How To Help Your Teen Apply To College
Unfortunately, most Americans don't have the resources to hire private tutors and consultants. And the high school counselors in charge of helping them are completely overtaxed: On average, for every counselor at a public high school, there are a whopping 376 students.
To level the playing field, Jon Carson started the College Guidance Network (CGN). The company partners with higher education pros and leverages AI to help students and parents every step of the way and help them make the best decision — whether that leads to a university, a trade school, or a gap year.
'Our mission is to democratize expertise,' he tells us.
We spoke to Carson about what parents can do to support their kids through this important stage of life, why fewer teens are opting to head straight to a four-year university, and more.
Carson: I ran the largest college advising company in the country, so I'm familiar with the space. About 6 percent of the U.S. market uses advisors, and they're quite expensive, but aren't often good. What we've built is guidance in a box: I think of it as Masterclass meets AI for college planning. We create a personalized roadmap: You tell us a little about yourself and your goals and interests, and we assemble checklists and detailed project plans tailored specifically to your needs. We also have over 375 nationally recognized experts to help parents navigate the ins and outs of the application process, how to afford paying for college, and thinking about ROI — which is becoming ever more important as AI starts to eat into entry-level jobs.
The ROI equation used to be highly skewed toward the investment piece. People were concerned about how much it'd cost and the loans they'd have to take out, but it was kind of a risk-free decision; all escalators went up. Now that's not really the case. It's become a much riskier decision. The percentage of high schoolers considering a four-year college is 45 percent — down 7 percent since the Covid era. A lot are going to community colleges, a bunch are doing gap years, the military's becoming more appealing.
The first thing — and it's completely understandable — is that parents get too anxious. They can be overbearing or just not quite their best selves. So, the first thing I'd say is that you have to calm down because it'll help you make the best decision. The second thing is that they need to be more inquisitive about how an institution will help their kid in career placement. I think too often parents place too much importance on prestige. You've got to pull away and think about this like a financial decision — and don't get caught up in the other things.
The earlier you get started, the better. We start our roadmaps in the ninth grade, and help kids start thinking about their summer jobs, how it'll reflect on their applications and things like that.
I'd also tell parents that they should have monthly meetings to have a space to talk about this. We did ours on the first Saturday of every month at 11 a.m. What that did was deescalate conflict, because it made them feel like I wasn't nagging them all the time, and we had a designated space for those conversations. The other thing is that parents and students should really think of themselves as a team. This is a journey that they're taking together.
This interview has been edited and condensed for clarity.
The post How To Help Your Teen Apply To College appeared first on Katie Couric Media.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
15 minutes ago
- Newsweek
Map Shows Where Xi Jinping Is More Popular Than Donald Trump
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Confidence in President Donald Trump and views of the United States have fallen among the world's major economies over the past year, while China and its leader, Xi Jinping, have risen slightly in popularity, according to Pew Research Center's spring survey. In nine of the 24 nations polled, excluding the United States, confidence in the Chinese president to do the right thing regarding world affairs was higher than confidence in Trump, according to Pew's report. The sentiment was found in around one-fourth of respondents in Canada and over one-third of those polled in Mexico. Why It Matters Global perceptions of the leaders of the world's two biggest economies play a role in shaping alliances, trade, and international diplomacy. The findings in the Pew survey—released in June and July, respectively—highlight complex and increasingly polarized attitudes toward U.S. leadership under Trump and China under Xi. Pew's spring survey polled over 30,000 people from January 8 to April 26, before the United States joined Israel in attacking Iran's nuclear sites and while Trump's policy of tariffs had largely yet to be finalized. What To Know Trump received mostly negative ratings in the survey of 24 economies but was more popularity than Xi in 13 nations, according to Newsweek's analysis of the results. In Greece and Kenya, confidence in Trump and Xi was tied at 37 and 64 percent, respectively. In the United States, where there was no related data for Trump, 75 percent of Americans said they had no confidence in Xi to do the right thing regarding world affairs, compared to 13 percent who said the opposite. More than half of respondents in 19 of the 24 countries said they lacked confidence in Trump's leadership, the poll showed. "Majorities in most countries also express little or no confidence in Trump's ability to handle specific issues, including immigration, the Russia-Ukraine war, U.S.-China relations, global economic problems, conflicts between Israel and its neighbors, and climate change," Pew said. When asked about Trump's personal characteristics, most described him as arrogant and dangerous, while relatively few saw him as honest, the center said. Nevertheless, majorities in 18 countries viewed Trump as a strong leader. Respondents in Israel, Nigeria and Turkey had become more likely to give the U.S. a favorable rating since last year. Israel and Nigeria were two of the five nations—along with Hungary, India and Kenya—where at least half of adults expressed confidence in Trump's handling of world affairs. While views of China and Xi have improved slightly over the past year, many people lacked confidence in Xi to do the right thing on world affairs, Pew said. Ratings for Xi were highest in Kenya and Nigeria, where about two-thirds of adults had confidence in him. Views were more mixed in South Africa, Pew said. In Europe, Latin America and North America, views of Xi were more negative than positive. The same was true in Turkey and Israel. People in four of the five Asia-Pacific countries surveyed mostly lacked confidence in Xi. In Japan, for instance, only 8 percent of those surveyed had confidence in him. But in Indonesia, 53 percent of people had confidence in Xi. Overall, confidence in Xi was lower in high-income countries than in middle-income ones, Pew said. But few people in the countries surveyed had confidence in either Trump or Xi to do the right thing regarding world affairs. What People Are Saying Pew Research Center: "In many of the countries surveyed, views of the U.S. have turned significantly more negative over the past year, while views of China have turned slightly more positive." Steven Cheung, White House spokesman, told NPR on June 12: "President Trump is the president of the American people and his priority is to work on their behalf, nobody else's." He added that the "overwhelming majority of Americans support his America First agenda." What Happens Next Future poll results will show the impact on Trump's standing of the airstrikes on Iran's nuclear program and of his policy on tariffs. International opinion polls are unlikely to play a significant role in White House policy, which under Trump has made America itself the overwhelming priority.
Forbes
40 minutes ago
- Forbes
How This New Biotech Billionaire Outmaneuvered Merck In China
M ichelle Xia spent a dozen years in research and biotech in the U.S. before relocating back to her native China for a job at American life sciences contract research company Crown Bioscience. It didn't take long for her to realize that patients in her home country needed to wait a much longer time than Americans to get the newest and best medicines. Back then, she says, it took eight to ten years for drugs that had been approved in the U.S. to become available in China. 'There was not much innovation in China' in drug development then, Xia recalls. China was producing copies of U.S. drugs, but with a big lag time. Armed with the ambition to change that and ample industry experience, she launched a biotech company in 2012 with two former Crown Bioscience colleagues and one other cofounder in the southern city of Zhongshan–west of Hong Kong. She took the lead as CEO, chairwoman and president of the startup, which they named Akeso–after a Greek goddess of healing. Now, five years after taking Akeso public on the Hong Kong Stock Exchange, the company's standout lung cancer drug has captured outsized attention in the pharmaceutical world. In a Phase 3 trial in China last year comparing Akeso's drug ivonescimab to Merck's Keytruda–the world's best-selling drug, with nearly $30 billion in 2024 sales–the Akeso drug outperformed Keytruda. The fact that a drug from a little known Chinese firm beat Merck's bestseller has led to a runup in Akeso's shares, which nearly tripled in value in the past year. That has turned 58-year-old Xia into a billionaire–with a $1.2 billion fortune, based on her and her family's 8.5% stake in the company, Forbes estimates. She is one of just nine Chinese women billionaires in healthcare (including two who inherited their fortunes)–and one of 13 self-made women billionaires in healthcare globally. More important to Xia is that her company has been an innovator. For its much-heralded cancer compound, Akeso combined two existing methods into one injectable drug: stimulating the immune system to attack the cancer cells and starving the cancer by cutting off the blood supply to the tumors. 'Usually that strategy [of combining two methods] is significantly ignored,' says Robert Booth, a former senior scientific executive at Roche and other firms and now a board member at Summit Therapeutics, which in 2022 licensed ivonescimab from Akeso for markets including the U.S., Canada, Europe and Japan. 'Michelle wasn't afraid to try that. She is confident in her own scientific judgement.' Akeso's achievements are part of a recent wave of success for Chinese biopharma companies. Nearly one-third of drug candidates licensed by large pharmaceutical firms came from Chinese companies last year, up from zero in 2019, according to research firm DealForma. In April, a U.S. congressional commission, the National Security Commission on Emerging Biotechnology, warned in a report that the U.S. risks losing its edge in biotech–and that the government should put $15 billion in funding over five years to support biotech research and manufacturing. 'Over the past five years, China has transitioned from being a nice to watch market to a central pillar of global biopharma innovation,' PwC's pharmaceutical and life science deals leader Roel van den Akker wrote in May. Some of that progress is fueled by Chinese scientists who studied or worked in the U.S. and then moved back to China– just like Xia did. Xia, who uses her given first name, Yu, in China, grew up in Gansu province in the country's northwest, the daughter of two university-educated engineers. After getting a degree in biochemistry at Sun Yat-sen University in Guangzhou in 1988, she obtained a scholarship and got a doctorate in molecular biology and microbiology from Newcastle University in the U.K. In 1996, she moved to the U.S. to do cancer research in a lab at the University of Louisville, in Kentucky, where she had some friends. Four years later she took a job at Celera Genomics–a company best known for its founder, Craig Venter, and his work on the first draft sequence of the human genome. Summit Therapeutics' board member Booth became chief scientific officer of Celera in 2002 and organized research committee meetings that involved senior scientists, in part to train the younger staff. 'Michelle was probably the most junior scientist to join those meetings. She would ask the most probing questions,' he recalls. Booth also set her to work using a complicated assay–a laboratory test employed in drug development–that had taken four very experienced scientists 10 weeks to get it to work when he was at Roche. 'I expected it to take months, but in two weeks she was producing good, reproducible results,'' he says. 'She was a very accomplished scientist, highly productive, and humble.' She later went on to work at Bayer and two other companies, and while in America obtained U.S. citizenship. Xia put her results-oriented focus to work when she and her Chinese colleagues launched Akeso. At the outset, she and her partners were determined to recruit the best university graduates, so they traveled 50 miles to Guangzhou—home to several good universities—to interview students in a conference room at a hospital where a friend worked, she says via Zoom from China, smiling at the memory. Finding private investors was also difficult at first, but Xia's team initially raised about $3 million from wealthy southern Chinese entrepreneurs. In 2015, Xia heard that pharma giant Merck was looking to license an immunotherapy drug candidate to target a protein called CTLA-4. It turned out that Akeso had one in early stage development. Xia, who had met someone from Merck's business development team at a conference, reached out and ended up arranging a deal to license Akeso's drug candidate to Merck for $200 million. It was the first time a Chinese company licensed a lab-developed protein (called a monoclonal antibody) to a global big pharma firm. 'That was a very good validation for us,' Xia recalls. 'We won [that deal] because of our quality and our speed.' Xia has organized Akeso to emphasize scientific advances, with nearly a third of the company's 3,500 employees working in research and development. 'We focus on science and biology and the most advanced technology,' says Xia. 'I think that makes the difference.' Since it was founded 13 years ago, Akeso has gotten five of its drugs approved by China's regulator–including its Keytruda competitor, ivonescimab. Two more drugs it developed and licensed to other companies in China were also approved. Meanwhile, another of its drugs, to treat a rare form of head and neck cancer called nasopharyngeal cancer, was also approved by the U.S. Food and Drug Administration in April. Revenue for the company is expected to grow 59% this year to nearly $470 million, while it's likely to post a net loss of $27 million, according to analysts at Hong Kong-based CMB International. The biggest factor putting Akeso into the spotlight of global pharma was its development of cancer drug ivonescimab. While Akeso had advanced the drug to Phase 3 trials and had presented promising research at ASCO, the big annual oncology conference, in 2022 big pharma was hesitant to do deals with Chinese companies. Says Ken Clark, a longtime biotech lawyer at Wilson Sonsini Goodrich & Rosati and a board member of Summit Therapeutics, 'All of the pharma companies passed on ivonescimab primarily because they didn't believe the data.' Luckily for Akeso, Summit's co-CEOs Maky Zanganeh and Bob Duggan, both now U.S. billionaires, had instructed their small team that same year to scour the globe for a drug in Phase 3 trials to license. One executive who was originally from China, Fong Clow, suggested looking there, and within months the Summit team had narrowed their focus to Akeso's drug. It turned out that Xia, Zanganeh and Duggan had a common tie: A drug candidate that Xia had worked on at Celera Genomics in the early 2000s was later purchased by Pharmacyclics, Duggan and Zanganeh's previous biotech company. Under their leadership, Pharmacyclics took the drug–called Imbruvica–through to FDA approval in 2013 for treatment of chronic lymphocytic leukemia, the most common form of leukemia. It became a blockbuster, and drug giant AbbVie bought Pharmacyclics for $21 billion in 2015. That connection helped give Xia confidence in Zanganeh and Duggan, both of whom had unorthodox backgrounds for biopharma executives: Zanganeh started as a dentist and Duggan, a serial entrepreneur, had run a cookie company, a needlepoint kit seller and more before investing in a robotic surgical company, where he met Zanganeh. The two teams soon recognized they both had entrepreneurial cultures. 'They found me, and I think it's a perfect fit,' says Xia. Akeso and Summit inked their licensing deal in December 2022, with Summit agreeing to pay $500 million upfront plus up to $4.5 billion in potential milestone payments. (Summit is now conducting its own Phase 3 trials of the Akeso drug in order to get approval from the U.S. FDA.) Xia joined Summit's board the next month. 'From the start, she built a company that could handle every step of drug development—from discovery to manufacturing—all under one roof. This gave Akeso speed, flexibility, and control in an industry where timing is everything,' Zanganeh says via text message. At a lung cancer conference in San Diego in September last year, Akeso announced the results of its head to head Phase 3 clinical trial with Merck's Keytruda for patients with a specific type of lung cancer. The patients on Akeso's drug went a median 11.1 months before the cancer returned, compared to 5.8 months for those taking Keytruda. Akeso's stock jumped 16% on the news the next day. Friends from around China and the U.S. reached out to congratulate Xia. Xia has even bigger goals. Akeso already has more than a dozen drug candidates it developed in clinical trials, and she wants to push the company beyond cancer drugs to pursue treatments for neurodegenerative diseases and autoimmune diseases, particularly as China's population ages. That means investing in new technology and new types of drugs, all with the goal of serving patients. Says Xia: 'We want to join the club and become a great company.' More from Forbes Forbes This AI Founder Became A Billionaire By Building ChatGPT For Doctors By Amy Feldman Forbes How The Healthcare Industry Can Address Delays In Psychiatric Care By Amanda Marlar Forbes Meet India's Self-Made Biologics Brewmaster Billionaire By Amy Feldman Forbes Catalysts In Innovation: A Doctor's Dream Impacts Healthcare By Hansa Bhargava
Yahoo
42 minutes ago
- Yahoo
Mastercard Launches New Benefits, Ultra-Exclusive Card For High Spenders
Mastercard (NYSE:MA) on Wednesday announced it is launching a new set of benefits called The Mastercard Collection to meet a major shift in how people, especially Americans, want to spend their time and money. New research from the company shows that consumers are choosing to invest in meaningful experiences with family and friends, rather than buying more stuff. Mastercard wants to help make those moments easier, more special, and more accessible. With the Mastercard Collection, cardholders can get perks that make going out to eat, traveling, and enjoying live entertainment more means easier access to hard-to-book restaurants, early ticket sales, better concert and sports seats, and smoother airport experiences. Mastercard is even adding exclusive dining lounges at select airports to help travelers relax and enjoy good food before they board. The company is also introducing its most premium card yet, World Legend Mastercard, aimed at higher-spending users who want one-of-a-kind experiences wherever they go. This new card will be available in the U.S. starting in the third quarter of 2025 and will expand to other countries afterward. While Mastercard's stock has seen a gain of nearly 5% year-to-date, it has slightly underperformed the S&P 100 Index, which includes Mastercard and has risen over 6% during the same period. This recent performance comes amidst broader shifts in the payments industry. The increasing adoption of stablecoins and mounting regulatory pressures have begun to exert downward pressure on the stock performance of both Visa (NYSE:V) and Mastercard. Investors have shown caution and are concerned that stablecoins could bypass the traditional payment networks that these companies rely on, potentially impacting their revenues and, subsequently, their share prices. Furthermore, shares of several payments and fintech companies, including Mastercard, recently experienced a decline after JPMorgan Chase (NYSE:JPM) unveiled plans last week to implement substantial fees for accessing customer bank account data. The announcement has sparked concerns across the industry about rising data costs and potential disruptions to digital payment services. Price Action: Mastercard shares closed down 0.48% at $550.36 on Tuesday. Image via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? MASTERCARD (MA): Free Stock Analysis Report This article Mastercard Launches New Benefits, Ultra-Exclusive Card For High Spenders originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
